{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:55:21Z","timestamp":1722887721111},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"DOI":"10.7759\/cureus.14768","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T10:50:26Z","timestamp":1619779826000},"source":"Crossref","is-referenced-by-count":2,"title":["Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-\u03b1) Agents in Crohn\u2019s Disease"],"prefix":"10.7759","author":[{"given":"Sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn disease: epidemiology, diagnosis, and management","volume":"92","author":"Feuerstein JD","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017, 92:1088-103. 10.1016\/j.mayocp.2017.04.010","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.152","article-title":"Protagonist: Crohn's disease recurrence can be prevented after ileal resection","volume":"51","author":"Rutgeerts P","year":"2002","unstructured":"Rutgeerts P. Protagonist: Crohn's disease recurrence can be prevented after ileal resection. Gut. 2002, 51:152-3. 10.1136\/gut.51.2.152","journal-title":"Gut"},{"key":"ref3","article-title":"Metronidazole therapy for Crohn's disease and associated fistulae","volume":"79","author":"Jakobovits J","year":"1984","unstructured":"Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984, 79:533-40.","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103","article-title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases","volume":"68","author":"Burmester GR","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BA, et al.. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009, 68:1863-9. 10.1136\/ard.2008.102103","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.10.039","article-title":"American Gastroenterological Association Institute technical review on the management of Crohn\u2019s disease after surgical resection","volume":"152","author":"Regueiro M","year":"2017","unstructured":"Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S. American Gastroenterological Association Institute technical review on the management of Crohn\u2019s disease after surgical resection. Gastroenterology. 2017, 152:277-295.e3. 10.1053\/j.gastro.2016.10.039","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection","volume":"150","author":"Regueiro M","year":"2016","unstructured":"Regueiro M, Feagan BG, Zou B, et al.. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology. 2016, 150:1568-7. 10.1053\/j.gastro.2016.02.072","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.7.1011","article-title":"Adalimumab for the treatment of Crohn's disease","volume":"8","author":"Devlin SM","year":"2008","unstructured":"Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther. 2008, 8:1011-9. 10.1517\/14712598.8.7.1011","journal-title":"Expert Opin Biol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld N","year":"2004","unstructured":"Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004, 15:280-94. 10.1080\/09546630410017275","journal-title":"J Dermatolog Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s3292","article-title":"Adalimumab for the treatment of Crohn's disease","volume":"2","author":"Cassinotti A","year":"2008","unstructured":"Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008, 2:763-77. 10.2147\/btt.s3292","journal-title":"Biologics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou E","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-\u03b1 blockers. Curr Neurol Neurosci Rep. 2017, 17:36. 10.1007\/s11910-017-0742-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0055-1","article-title":"CNS demyelination during anti-tumor necrosis factor alpha therapy","volume":"253","author":"Bellesi M","year":"2006","unstructured":"Bellesi M, Logullo F, Di Bella P, Provinciali L. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol. 2006, 253:668-9. 10.1007\/s00415-005-0055-1","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/671935","article-title":"Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature","volume":"2013","author":"Andreadou E","year":"2013","unstructured":"Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013, 2013:671935. 10.1155\/2013\/671935","journal-title":"Case Rep Neurol Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.140596","article-title":"Factor XI deficiency diagnosed following use of adalimumab","volume":"46","author":"Cetin G","year":"2014","unstructured":"Cetin G, Karatoprak C, Kiskac M, Zorlu M, Rezvani A, Cikrikcioglu MA. Factor XI deficiency diagnosed following use of adalimumab. Indian J Pharmacol. 2014, 46:553-4. 10.4103\/0253-7613.140596","journal-title":"Indian J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1808227","article-title":"Adalimumab-associated acquired hemophilia in a patient with scleritis","author":"Liberman P","year":"2020","unstructured":"Liberman P, Burkholder BM. Adalimumab-associated acquired hemophilia in a patient with scleritis. Ocul Immunol Inflamm. 2020, 1-3. 10.1080\/09273948.2020.1808227","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58270-rare-and-serious-adverse-effects-of-anti-tumor-necrosis-factor-alpha-tnf--agents-in-crohns-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:03Z","timestamp":1707507003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58270-rare-and-serious-adverse-effects-of-anti-tumor-necrosis-factor-alpha-tnf--agents-in-crohns-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.14768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,30]]}}}